Login

Ownership

13F as of Q2 2026 · 122.4M shares outstanding

Who owns CATALYST PHARMACEUTICALS, INC.?

By type of holder
Institutions 88.1% Everyone else 11.9%

No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".

Concentration Top 10 holders own 45.1%
BlackRock, Inc. 15.7% · State Street Corp 6.2%
Institutional ownership
88.1%
+2.6 pts vs last qtr
Institutional holders
398
+12 vs last qtr
Net shares bought
+3.2M
by institutions in Q2 2026
New / sold out
99 / 87
positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026
  • Glazer Capital, LLC NEW +3.6M
  • HBK Investments L P NEW +2.8M

Sign up to see all 5.

Biggest sellers in Q2 2026
  • Deerfield Management Company, L.P. SOLD OUT −3.9M
  • Janus Henderson Group PLC SOLD OUT −2.0M

Sign up to see all 5.

Who is planning to sell?

Notices of proposed sale, last 12 months
$622K
1 notice from 1 person
Shares covered
26.7K
0.02% of the company
Arranged in advance
0%
of the value is under a 10b5-1 plan
Under a 10b5-1 plan No plan
$0$311.0K$621.9KDec 2025: $621.9K without a planDecJanFebMarAprMayJunJulAugSepOctNov
Largest proposed sellers
  • Harper Molly Director $622K
Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2016–FY2025
+53.6%
+4.88% a year
Each share's claim on the business
−34.9%
shrank without buying or selling a share
Spent on buybacks vs paid in stock
$44.3M vs $93.1M
over 10 fiscal years
Diluted shares, split-adjusted
80.4M104.5M128.5M2016: 82.9M shares'162017: 85.8M shares'172018: 102.6M shares'182019: 106.0M shares'192020: 106.2M shares'202021: 107.8M shares'212022: 111.4M shares'222023: 113.8M shares'232024: 124.9M shares'242025: 127.3M shares'25
Buybacks Stock-based comp
$0$12.7M$25.3M2016 buybacks: $02016 stock comp: $1.8M'162017 buybacks: $02017 stock comp: $2.4M'172018 buybacks: $02018 stock comp: $3.6M'182019 buybacks: $02019 stock comp: $3.8M'192020 buybacks: $02020 stock comp: $6.3M'202021 buybacks: $12.1M2021 stock comp: $6.1M'212022 buybacks: $6.9M2022 stock comp: $7.9M'222023 buybacks: $02023 stock comp: $14.3M'232024 buybacks: $02024 stock comp: $22.3M'242025 buybacks: $25.3M2025 stock comp: $24.8M'25

How patient are the owners?

Institutional shares by how long they've been held
5+ years62% 3–5 years8% 1–3 years9% Under 1 year20%
Quarterly turnover
27.8%
of institutional shares changed hands
Top 10 managers, median time held
5 years

Super Investors

Investment managers reporting CATALYST PHARMACEUTICALS, INC. on Form 13F
B
BlackRock, Inc.
Shares
19.2M
% of company
15.66%
Change vs last qtr
+384.3K (+2.0%)
Held since
≤2021
SS
State Street Corp
Shares
7.6M
% of company
6.23%
Change vs last qtr
+764.0K (+11.1%)
Held since
≤2021

28 more super investors behind a free account

See every manager holding CATALYST PHARMACEUTICALS, INC., how their position has changed, and how long they've held it.

Sign up free

Institutional Funds

Mutual funds and ETFs reporting CATALYST PHARMACEUTICALS, INC. on Form N-PORT; together they hold 44.0% of the company
Position value
$218M
% of company
5.66%
% of the fund
0.20%
As of
June 30, 2026
AU
American Century ETF Trust
Position value
$130M
% of company
3.40%
% of the fund
0.48%
As of
May 31, 2026

23 more funds behind a free account

See every fund holding CATALYST PHARMACEUTICALS, INC. and how much of the fund the position is.

Sign up free

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support